Mitochondrial Dysfunction Correlates with Brain Amyloid Binding, Memory, and Executive Function in Down Syndrome: Implications for Alzheimer’s Disease in Down Syndrome
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Abstract
Background/Objectives: Mitochondrial dysfunction is increasingly recognized as a central contributor to neurodegenerative diseases and age-related cognitive decline. Individuals with Down syndrome (DS) are at high risk of neurodegeneration due to Alzheimer’s disease (AD). This study aims to explore the relationship between mitochondrial dysfunction, brain amyloid-beta (Aβ) deposition, and cognitive decline in this population. Methods: We investigated mitochondrial function, brain amyloid-beta burden, and cognitive performance in a pilot study of a cohort of 10 eligible adults with DS selected from a sample of 28 individuals with DS. Phosphorus-31 magnetic resonance spectroscopy (31P-MRS) was used to assess mitochondrial function in skeletal muscle using a post-exercise paradigm, while positron emission tomography using 11C-Pittsburgh compound B (PiB-PET) measured brain Aβ deposition. Cognitive performance was evaluated using the Cambridge Cognitive Examination adapted for individuals with Down syndrome (CAMCOG-DS) and executive function batteries. Results: Significant correlations were observed between slowed phosphocreatine (PCr) recovery in muscle and increased Aβ deposition in key brain regions, particularly the striatum. Cognitive performance inversely correlated with mitochondrial function, with pronounced deficits in memory and executive function tasks. Notably, an individual carrying the APOE-ε4 allele exhibited the poorest mitochondrial function, highest Aβ burden, and most severe cognitive impairment, suggesting a potential interaction between genetic risk and mitochondrial health. Conclusions: These findings highlight the role of mitochondrial dysfunction in DS-associated AD (DSAD) and its impact on cognition in adults. The results support targeting mitochondrial pathways as a potential therapeutic strategy to mitigate AD progression in DS populations. Further research with larger cohorts and longitudinal designs is needed to clarify causative mechanisms and develop effective interventions.
Description
Peer reviewed: True
Acknowledgements: We would like to wholeheartedly thank the participants and families who took part in this study. The authors also thank the staff at the Down Syndrome Association UK; the Cambridge UK National Institute for Health and Care Research (NIHR) Clinical Research Facility (Cambridge Clinical Research Centre); the radiographers at the Wolfson Brain Imaging Centre; Ursula Quinn at the University of Cambridge; Angela Pyle, Jennifer Duff, and Gavin Falkous at Newcastle University; and Graham Kemp at the University of Liverpool. The views expressed here are those of the authors and not necessarily those of the Department of Health, the NIHR, or other funders. All research at the Department of Psychiatry in the University of Cambridge is supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the NIHR Applied Research Collaboration East of England. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Publication status: Published
Funder: Health Foundation
Funder: National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Health Research and Care
Keywords
Journal Title
Conference Name
Journal ISSN
Volume Title
Publisher
Publisher DOI
Rights and licensing
Sponsorship
Alzheimer’s Research UK (ARUK-PG2015-23, ARUK-PPG2017B-72)
The Baily Thomas Charitable Trust (TRUST/RNA/AC/TM/2668/5218)
Addenbrooke’s Charitable Trust (9727 23/12)
NIHR Cambridge Clinical Research Facility (NIHR Cambridge Biomedical Research Centre (NIHR203312)